Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
56 participants
INTERVENTIONAL
2007-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pandemic Influenza Plasmid DNA Vaccines (Needle-Free)
NCT00694213
VRC 308: An Open-Label Phase I Study of the Safety and Immunogenicity of an Investigational H1 DNA Influenza Vaccine, VRC-FLUDNA057-00-VP, in Healthy Adults 18-70 Years Old
NCT00973895
A Study to Learn How Safe, Tolerable and Capable of Producing an Immune Response is, a Modified RNA Vaccine Against Pandemic Influenza
NCT06179446
A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza
NCT05227001
A Safety and Immunology Study of a DNA Trivalent Influenza Vaccine
NCT00375206
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
2
VCL-IPT1
IM, 0.5 mg/mL, 2 injections, 0 and 21 days
3
VCL-IPT1
IM, 1 mg/mL, 2 injections, 0 and 21 days
4
VCL-IPM1
IM, 1 mg/mL, 2 injections, 0 and 21 days
5
PBS
IM, 1 mL, 2 injections, 0 and 21 days
1
VCL-IPT1
IM, 0.1 mg/mL, 2 injections, 0 and 21 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
VCL-IPT1
IM, 0.1 mg/mL, 2 injections, 0 and 21 days
VCL-IPT1
IM, 0.5 mg/mL, 2 injections, 0 and 21 days
VCL-IPT1
IM, 1 mg/mL, 2 injections, 0 and 21 days
VCL-IPM1
IM, 1 mg/mL, 2 injections, 0 and 21 days
PBS
IM, 1 mL, 2 injections, 0 and 21 days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Able to provide informed consent and be followed for 6 months
Exclusion Criteria
* No evidence of immunodeficiency or pregnancy
* No laboratory or evidence of clinically significant medical disease
* No history of previous pDNA immunization
* No influenza immunization within the past 30 days
* No blood donations within 30 days of screening visit
* No history of bleeding disorder
* No use of aspirin and/or anticoagulants within 2 weeks of the administration of the investigational vaccines
18 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vical
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Vical Incorporated
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Don Guterwill, BS, MT
Role: STUDY_CHAIR
Vical
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Accelovance
San Diego, California, United States
SNBL
Baltimore, Maryland, United States
SUNY at Stonybrook, Stony Brook Medical Center
Stony Brook, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IPT1-101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.